XML 20 R5.htm IDEA: XBRL DOCUMENT v3.24.2
Unaudited Condensed Interim Consolidated Statements of Changes in Shareholders' Equity - CAD ($)
Common shares
Preferred shares
Additional paid-in capital
Deficit
Accumulated Other Comprehensive Loss
Total
Beginning balance at Dec. 31, 2022   $ 31,516 $ 77,302,736 $ (72,190,747) $ (1,200,516) $ 3,942,989
Beginning balance (in shares) at Dec. 31, 2022 116,521,343          
Net Income (Loss)       (6,367,772)   (6,367,772)
Share capital issued through private placement     7,765,072     7,765,072
Share capital issued through private placement (in shares) 4,437,184          
Share issue costs     (606,547)     (606,547)
Fair value of lender warrants     116,177     116,177
Exchange differences on translation of foreign operations         (272,337) (272,337)
Ending balance at Mar. 31, 2023   31,516 84,577,438 (78,558,519) (1,472,853) 4,577,582
Ending balance (in shares) at Mar. 31, 2023 120,958,527          
Beginning balance at Dec. 31, 2023   31,516 116,069,973 (104,566,816) (1,788,987) 9,745,686
Beginning balance (in shares) at Dec. 31, 2023 149,300,920          
Net Income (Loss)       (9,347,180)   (9,347,180)
Exercise of options, net (shares) 126,259          
Share-based payment     389,612     389,612
Exchange differences on translation of foreign operations         (137,237) (137,237)
Ending balance at Mar. 31, 2024   $ 31,516 $ 116,459,585 $ (113,913,996) $ (1,926,224) $ 650,881
Ending balance (in shares) at Mar. 31, 2024 149,427,179